Intermountain Healthcare researchers stopped the Hydroxychloroquine vs. Azithromycin for Hospitalized Patients with Suspected or Confirmed COVID-19 (HAHPS) clinical trial Friday, June 19, when clear answers about hydroxychloroquine were received from the national ORCHID trial showing the drug doesn’t benefit hospitalized patients with COVID-19.

The HAHPS trial, a collaboration between Intermountain and University of Utah Health, enrolled 85 patients at 13 Utah hospitals in 11 weeks from April 3 through June 19. Clinical trial staff are continuing to monitor patients already enrolled and will release formal findings as soon as information has been gathered from all enrolled patients following the 28-day monitoring period for the 85th patient.

Intermountain’s inpatient hydroxychloroquine trial closed since the question has been answered definitively and independently by the national ORCHID trial.

After ORCHID’s safety monitoring board recommended the stopping of its trial, Intermountain followed the national trial’s safety experts who “determined that while there was no harm, the study drug was very unlikely to be beneficial to hospitalized patients with COVID-19.”

Intermountain’s trial, HAHPS, was explicitly designed to run as a complementary trial to ORCHID, which was coordinated through the Prevention and Early Treatment of Acute Lung Injury (PETAL) Network. Intermountain is one of several trial centers in the PETAL Network.

Intermountain is committed to supporting options for our patients and their families to participate in state-of-the-art research studies that provide access to the most promising treatments for COVID-19. Patients admitted to Intermountain facilities continue to have access to world-class medical care independent of clinical trials.

More information about what researchers learned from the trial, why it’s important, and what’s next is available here.